86 results on '"Kuemmerle‐Deschner, J. B."'
Search Results
2. POS1183 PREGNANCY OUTCOMES IN CAPS PATIENTS ON IL-1 INHIBITION
3. AB1372 PEDIATRIC AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN TREATMENT-RESISTANT AUTOIMMUNE DISEASES: A REAL-LIFE SINGLE-CENTER EXPERIENCE
4. Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry
5. AB1496 LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH HIDS (HYPER-IGD SYNDROME) − INTERIM ANALYSIS OF THE RELIANCE REGISTRY
6. POS0740 VALIDATION OF THE PEDIATRIC BEHÇET DISEASE CRITERIA (PEDBD): A REAL LIFE CONSENSUS-BASED APPROACH
7. POS1570 LONG-TERM SAFETY AND EFFECTIVENESS OF CANAKINUMAB IN FAMILIAL MEDITERRANEAN FEVER (FMF) – 36-MONTH DATA FROM THE RELIANCE REGISTRY
8. POS1573 LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH TRAPS (TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PERIODIC SYNDROME) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY
9. POS1558 LONG-TERM SAFETY OF CANAKINUMAB IN AUTOINFLAMMATORY PERIODIC FEVER SYNDROMES – 48-MONTH DATA FROM THE RELIANCE REGISTRY
10. OP0252 LONG-TERM SAFETY AND EFFECTIVENESS OF CANAKINUMAB IN CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) – 4-YEARS DATA FROM THE RELIANCE REGISTRY
11. Brief Report: Clinical and Molecular Phenotypes of Low‐Penetrance Variants of NLRP3: Diagnostic and Therapeutic Challenges
12. POS1376 LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH HIDS (HYPER-IgD SYNDROME) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY
13. POS1365 THE FMF&AID SURVEY - A PATIENT ORGANIZATION DRIVEN SURVEY FOR AUTOINFLAMMATORY DISEASES
14. POS1374 LONG-TERM SAFETY OF CANAKINUMAB IN PATIENTS WITH AUTOINFLAMMATORY DISEASES - INTERIM ANALYSIS OF THE RELIANCE REGISTRY
15. POS0221 LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH TRAPS (TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PERIODIC SYNDROME) – INTERIM ANALYSIS OF THE RELIANCE REGISTRY
16. POS0171 A STANDARDIZED ASSESSMENT OF TREATMENT AND OUTCOME OF NEWLY DIAGNOSED PATIENTS WITH JIA WITHIN THE PROKIND PROJECT – PATHWAYS FOR POLYARTICULAR JIA
17. POS0220 LONG-TERM SAFETY AND EFFECTIVENESS OF CANAKINUMAB IN CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES – 36-MONTH DATA FROM THE RELIANCE REGISTRY
18. OP0042 LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER (FMF) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY
19. A STANDARDIZED ASSESSMENT OF TREATMENT AND OUTCOME OF NEWLY DIAGNOSED PATIENTS WITH JIA WITHIN THE PROKIND PROJECT - PATHWAYS FOR POLYARTICULAR JIA
20. POS1199 CLINICAL MANIFESTATIONS OF SARS-CoV2 INFECTIONS IN CHILDREN AND ADOLESCENTS WITH RHEUMATIC AND MUSCULUSKELETAL DISEASES – SURVEY DATA FROM GERMANY
21. POS1380 LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH TRAPS (TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PERIODIC SYNDROME) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY
22. OP0092 LONG-TERM SAFETY AND EFFECTIVENESS OF CANAKINUMAB IN CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) – 30-MONTH DATA FROM THE RELIANCE REGISTRY
23. POS1379 LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER (FMF) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY
24. Supplement to: Use of canakinumab in the cryopyrin-associated periodic syndrome.
25. FRI0486 LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH AUTOINFLAMMATORY PERIODIC FEVER SYNDROMES – FIRST INTERIM ANALYSIS OF THE FMF/TRAPS/HIDS SUBGROUPS FROM THE RELIANCE REGISTRY
26. SAT0510 LONG-TERM EFFECTIVENESS OF CANAKINUMAB IN AID – INTERIM ANALYSIS OF THE CAPS SUBGROUP FROM THE RELIANCE REGISTRY
27. FRI0591 VALIDITY OF THE GERMAN VERSION OF BOTH THE PARENT ADHERENCE REPORT QUESTIONNAIRE (PARC) AND THE CHILD ADHERENCE REPORT QUESTIONNAIRE (CARQ) - DATA OF THE INCEPTION COHORT OF NEWLY DIAGNOSED PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS (ICON)
28. Canakinumab (Ilaris®) provides rapid response and sustained remission in patients across different severity phenotypes of Cryopyrin Associated Periodic Syndrome (CAPS): 0291
29. Predictors of Delayed Referral to a Pediatric Rheumatology Center
30. Interferon-α—a new therapeutic option in refractory juvenile Behçetʼs disease with CNS involvement
31. Stress fractures: diagnostic pitfalls in juvenile idiopathic arthritis
32. OP0163 LONG-TERM EFFECTIVENESS OF CANAKINUMAB IN PATIENTS WITH CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME
33. Miscellaneous Rheumatic Diseases [73-83]: 73. Is There a Delay in Specialist Referral of Hot Swollen Joint?
34. Takayasu-Arteriitis des Kindesalters nach allogener Stammzelltransplantation bei Hyper-IgE-Syndrom mit Nachweis einer NOD2-Mutation
35. LONG-TERM SAFETY AND EFFECTIVENESS OF CANAKINUMAB IN FAMILIAL MEDITERRANEAN FEVER (FMF) - 36-MONTH DATA FROM THE RELIANCE REGISTRY.
36. LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH TRAPS (TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PERIODIC SYNDROME) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY.
37. Cytokines and Inflammatory Mediators [30-39]: 30. The LPS Stimulated Production of Interleukin-10 is not Associated with -819C/T and -592C/A Promoter Polymorphisms in Healthy Indian Subjects
38. Concurrent Oral 1 - Therapy of rheumatic disease: OP4. Effectiveness of Rituximab in Rheumatoid Arthritis: Results from the British Society for Rheumatology Biologics Register (BSRBR)
39. Development of the autoinflammatory diseases damage index (ADDI)
40. Clinical and Molecular Phenotypes of Low-Penetrance Variants of NLRP3: Diagnostic and Therapeutic Challenges.
41. LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH HIDS (HYPER-IGD SYNDROME) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY.
42. LONG-TERM SAFETY OF CANAKINUMAB IN AUTOINFLAMMATORY PERIODIC FEVER SYNDROMES - 48-MONTH DATA FROM THE RELIANCE REGISTRY.
43. VALIDATION OF THE PEDIATRIC BEHÇET DISEASE CRITERIA (PEDBD): A REAL LIFE CONSENSUS-BASED APPROACH.
44. LONG-TERM SAFETY AND EFFECTIVENESS OF CANAKINUMAB IN CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) - 4-YEARS DATA FROM THE RELIANCE REGISTRY.
45. Takayasu-Arteriitis des Kindesalters nach allogener Stammzelltransplantation bei Hyper-IgE-Syndrom mit Nachweis einer NOD2-Mutation
46. THU0464 Safety Results from the B-Confident Registry in Canakinumab-Treated Patients with Cryopyrin-Associated Periodic Syndrome (CAPS)
47. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes
48. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes
49. Cytokines and inflammatory mediators: 25. Certolizumab Pegol has a Different Profile from the other Anti-TNFS, Including Golimumab, in a Variety of in Vitro Assays
50. Concurrent Oral 1 - Therapy of rheumatic disease: OP4. Effectiveness of Rituximab in Rheumatoid Arthritis: Results from the British Society for Rheumatology Biologics Register (BSRBR)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.